

Form C

Cover Page

Name of issuer:
OsNovum

Legal status of issuer:
Form: Corporation
Jurisdiction of Incorporation/Organization: WY
Date of organization: 6/9/2020

Physical address of issuer:
1051 Olson St. 361
Henderson NV 89011

Website of issuer:
http://www.OsNovum.com

Name of intermediary through which the offering will be conducted:
Wefunder Portal LLC

CIK number of intermediary:
0001670254

SEC file number of intermediary:
007-00033

CRD number, if applicable, of intermediary:
283503

Amount of compensation to be paid to the intermediary, whether as a dollar amount or a percentage of the offering amount, or a good faith estimate if the exact amount is not known at the time of the filing, for conducting the offering, including the amount of referral and any other fees associated with the offering:
7.5% of the offering amount upon a successful fundraise, and be entitled to reimbursement for out-of-pocket third party expenses it pays or incurs on behalf of the Issuer in connection with the offering

Any other direct or indirect interest in the issuer held by the intermediary, or any arrangement for the intermediary to acquire such an interest:
No

Type of security offered:
 Common Stock
 Preferred Stock
 Debt
 Other

If other, describe the security offered:
Target number of securities to be offered:
2,430

Price:
\$25.00000

Method for determining price:
Dividing pre-money valuation \$14,400,000.00 (or \$12,000,000.00 for investors in the first \$200,000.00) by number of shares outstanding on fully diluted basis.

Target offering amount:
\$60,750.00

Oversubscriptions accepted:
 Yes
 No

If yes, disclose how oversubscriptions will be allocated:
 Pro-rata basis
 First-come, first-served basis
 Other

If other, describe how oversubscriptions will be allocated:
As determined by the issuer

Maximum offering amount (if different from target offering amount):
\$1,070,000.00

Deadline to reach the target offering amount:
3/31/2021

NOTE: If the sum of the investment commitments does not equal or exceed the target offering amount at the offering deadline, no securities will be sold in the offering. Investment commitments will be canceled and committed funds will be returned.

Current number of employees:
4

Most recent fiscal year-end: Prior fiscal year-end:
Total Assets: \$0.00
Cash & Cash Equivalents: \$100.00
Accounts Receivable: \$0.00
Short-term Debt: \$0.00
Long-term Debt: \$0.00
Revolving/Sales: \$0.00
Cost of Goods Sold: \$0.00
Taxes Paid: \$0.00
Net Income: \$9.00
\$0.00

Select the jurisdictions in which the issuer intends to offer the securities:
AL, AK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, VA, WA, WV, WI, WY, BS, GU, PR, VI, 1V

Offering Statement

Respond to each question in each paragraph of this part. Set forth each question and any notes, but not any instructions therein, in their entirety. If disclosure in response to any question is responsive to one or more other questions, it is not necessary to repeat the disclosure. If a question or series of questions is inapplicable or the response is available elsewhere in the Form, either state that it is inapplicable, include a cross-reference to the responsive disclosure, or omit the question or series of questions.

Be very careful and precise in answering all questions. Give full and complete answers so that they are not misleading under the circumstances involved. Do not discuss any future performance or other anticipated event unless you have a reasonable basis to believe that it will actually occur within the foreseeable future. If any answer requiring significant information is materially inaccurate, incomplete or misleading, the Company, its management and principal shareholders may be liable to investors based on that information.

THE COMPANY

1. Name of issuer:
OsNovum

COMPANY ELIGIBILITY

2. Check this box to certify that all of the following statements are true for the issuer:

- Operated under and subject to, the laws of a State or territory of the United States or the District of Columbia.
- Not subject to the requirement to file reports pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934.
- Not an investment company registered or required to be registered under the Investment Company Act of 1940.
- Not ineligible to rely on this exemption under Section 4(a)(6) of the Securities Act as a result of disqualification specified in Rule 503(c) of Regulation Crowdfunding.
- Has filed with the Commission and provided to investors, to the extent required, the ongoing annual reports required by Regulation Crowdfunding during the two years immediately preceding the filing of this offering statement (or for such shorter period as required by the Commission to file such reports).
- Not a development stage company: (a) has a specific business plan or (b) has indicated that its business plan is to engage in a merger or acquisition with an unidentified company or companies.

INSTRUCTION TO QUESTION 2: If any of these statements are not true, then you are **NOT** eligible to rely on this exemption under Section 4(a)(6) of the Securities Act.

3. Has the issuer or any of its predecessors previously failed to comply with the ongoing reporting requirements of Rule 202 of Regulation Crowdfunding?

Yes No

DIRECTORS OF THE COMPANY

4. Provide the following information about each director (and any persons occupying a similar status or performing a similar function) of the issuer.

Director	Principal Occupation	Main Employer	Year Joined as Director
Roslyn Lilian Steiner	Biotech officer	OsNovum	2020
Gregory Gene Steiner	Biotech officer	OsNovum	2020

For three years of business experience, refer to [Appendix D: Director & Officer Work History](#).

OFFICERS OF THE COMPANY

5. Provide the following information about each officer (and any persons occupying a similar status or performing a similar function) of the issuer.

Officer	Positions Held	Year Joined
Daniel Vargas	Vice President	2020
Roslyn Lilian Steiner	President	2020
Roslyn Lilian Steiner	Secretary	2020
Roslyn Lilian Steiner	Treasurer	2020
Gregory Gene Steiner	CEO	2020

For three years of business experience, refer to [Appendix D: Director & Officer Work History](#).

PRINCIPAL SECURITY HOLDERS

6. Provide the name and ownership level of each person, as of the most recent practicable date, who is the beneficial owner of 20 percent or more of the issuer's outstanding voting equity securities, calculated on the basis of voting power.

Name of Holder	No. and Class of Securities Now Held	% of Voting Power Prior to Offering
Roslyn Lilian Steiner	2352000.0 Common	49.0
Gregory Gene Steiner	244800.0 Common	51.0

INSTRUCTION TO QUESTION 6: The above information must be provided as of a date that is no more than two days prior to the date of filing of this offering statement.

The following term "voting power" includes all securities for which the person directly or indirectly has or shares the voting power, which includes the right to vote or to direct the voting of such securities. If the person has the right to acquire voting power of such securities within 60 days, including through the exercise of any option, warrant or right, the conversion of a security, or other arrangement, or if securities are held by a member of the family, through corporations or partnerships, or otherwise in a manner that would allow a person to direct or control the voting of the securities for share in such direction or control, as, for example, a corporation they control, or a partnership they control. The term "beneficial owner" means a person who has the right to exercise voting power in connection with the "Holder of record Class of Securities Now Held." This includes outstanding voting equity securities, assuming all outstanding options are exercised and all outstanding convertible securities converted.

BUSINESS AND ANTICIPATED BUSINESS PLAN

7. Describe in detail the business of the issuer and the anticipated business plan of the issuer.

For a description of our business and our business plan, please refer to the attached Appendix A, Business Description & Plan. [202120120210 TO 0202120210](#). We shall provide your company's "holder profile as of an appendage (Appendix A) to the Form 2 in PDF format. The information will include all 602 items and "New items" listed in an as catalogued format. All tables will be transcribed.

This means that any information provided in your "holder profile will be provided to the SEC in separate tables and will be transcribed into the Form 2 in PDF format. This will make it easier for investors to read your profile under the Securities Act of 1933, which requires you to provide material information about your business and anticipated business plan. Please review your "holder profile carefully to ensure it provides all material information, is not false or misleading, and does not omit any information that could cause the information included to be false or misleading.

RISK FACTORS

A crowdfunding Investment Involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment.

In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document.

The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature.

These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.

8. Discuss the material factors that make an investment in the issuer speculative or risky:

Possible inability to acquire FDA clearance. The identical material is already cleared for dental use and has a safe and effective history, but the possibility still exists that we will not be able to acquire FDA clearance.

When the product is cleared by the FDA more funding may be required to bring the product to market.

Management team has a history of success gaining FDA clearance and loss of management could compromise likelihood of success.

The FDA and USDA is continually inspecting the facility and any violations could delay product progress.

The submission to the FDA usually takes a number of months to complete. We assume approximately 6 months but this could be extended if the FDA requires further to inspect.

OsNovum will initially operate in the facilities of Steinberg. Any conflict with Steinberg could compromise OsNovum. However, because Steinberg and OsNovum are under the same ownership and management and because Steinberg has a long stable history, owns the facilities and has no long term debt, OsNovum has a very stable partner.

COVID-19 can materially impact our business. It is unclear how long the COVID-19 pandemic will last and to what degree it could hurt our ability to generate revenues. For example, it could complicate our ability to procure materials and partnerships. There may be other effects stemming from this pandemic that are deleterious to our company, which we have not yet considered.

We will likely need to engage in equity, debt, or preferred stock financing in the future. We are currently in the process of raising capital to support our operations. This interest in debt securities could increase costs and negatively impact operating results. In addition, if, in the future, we need to raise more equity capital from the sale of stock, institutional or other investors may negotiate terms, at least as, and possibly more, favorable than the terms of your investment. Shares of our equity could be sold into any market which develops, which could adversely affect the market price.

While we have 15 years experience in the bone regeneration marketplace our limited operating history with OsNovum makes evaluating the business and future prospects difficult, and may increase the risk of your investment. We were incorporated in June 2020. To date, we have no revenues.

Our future success depends on the efforts of a small management team. The loss of services of the members of the management team may have an adverse effect on the Company. There can be no assurance that we will be successful in attracting and retaining other personnel we require to successfully grow our business.

Daniel Vargas is a part-time officer. As such, it is likely that the company will not make the same progress as it would if that were not the case.

INSTRUCTION TO QUESTION 8: Avoid generalized statements and include only those factors that are unique to the issuer. Discussion should be tailored to the issuer's business and the offering and should not repeat the factors addressed in the registration statement. No specific analysis of risk factors is required to be included.

The Offering

USE OF FUNDS

9. What is the purpose of this offering?

The Company intends to use the net proceeds of this offering for working capital and general corporate purposes, which includes the specific items listed in Item 10 below. While the Company expects to use the net proceeds from the Offering in the manner described above, it cannot specify with certainty the particular uses of the net proceeds that it will receive from this Offering. Accordingly, the Company will have broad discretion in using those proceeds.

10. How does the issuer intend to use the proceeds of this offering?

If we raise: **\$60,750**

Use of: 92.5% FDA Tests, 7.5% Wefunder fees

If we raise: **\$1,070,000**

Use of: 15% FDA Tests, 2.5% ISO Certification, 10% Regulatory Submission, 10% Professional, Legal, accounting, Funding Acquisition, 15% Capitol Improvements, 10% Production Equipment, 10% Product Delivery System, 20% Salaries, 7.5% Wefunder fees

ANS240512H10004210W10. An issuer must provide a reasonably detailed description of any intended use of proceeds such that investors are provided with an adequate amount of information to understand how the offering proceeds will be used, if an issuer has identified an range of possible uses, the issuer should identify and describe each individual use of the offering proceeds in a reasonable manner. If the issuer will receive proceeds in excess of the range identified, describe the reasons, methods, and timing for adjusting the intended use of proceeds. The issuer must describe the reasons, methods, and timing for adjusting the intended use of proceeds if it is necessary to do so to meet its obligations. Please include all possible uses of the proceeds of the offering, including any that may apply if the range of possible uses of proceeds is exceeded. If you do not do so, you may later be required to amend your form 10, including to not responsible for any failure by you to describe a potential use of offering proceeds.

DELIVERY & CANCELLATIONS

11. How will the issuer complete the transaction and deliver securities to the investors?

Book Entry and Use of XX Investments LLC as Transfer Agent and Custodian. Investments will be in book entry form. This means that the investor will not receive a certificate representing his or her investment. Each investment will be recorded in the name and account of the investor in the system of XX Investments LLC. XX Investments LLC will act as custodian and hold legal title to the investments for investors that enter into a Custodial and Voting Agreement with XX Investments LLC and will keep track of those investors' beneficial interests in the investments. In addition, investors' interests in the investments will be recorded in each investor's "My Investments" screen. The investor will also be emailed again the Investor Agreement and, if applicable, the Custodial and Voting Agreement. The Investor Agreement and, if applicable, the Custodial and Voting Agreement will also be available on the "My Investments" screen.

12. How can an investor cancel an investment commitment?

NOTE: Investors may cancel an investment commitment until 48 hours prior to the deadline identified in these offering materials.

The intermediary will notify investors when the target offering amount has been met. If the issuer reaches the target offering amount prior to the deadline identified in the offering materials, it may close the offering early if it provides notice about the new offering deadline at least five business days prior to such new offering deadline (absent a material change that would require an extension of the offering and reconfirmation of the investment commitment).

If an investor does not cancel an investment commitment before the 48-hour period prior to the offering deadline, the funds will be released to the issuer upon closing of the offering and the investor will receive securities in exchange for his or her investment.

If an investor does not reconfirm his or her investment commitment after a material change is made to the offering, the investor's investment commitment will be cancelled and the committed funds will be returned.

An Investor's right to cancel. An investor may cancel his or her investment commitment at any time until 48 hours prior to the offering deadline.

If there is a material change to the terms of the offering or the information provided to the investors about the offering and/or the Company, the investor will be given notice of the change and will have the right to cancel his or her investment commitment within five business days of receipt of the notice. If the investor does not reconfirm, he or she will receive notifications disclosing that the commitment was cancelled, the reason for the cancellation, and the refund amount that the investor is required to receive. If a material change occurs within five business days of the maximum number of days the offering is to remain open, the offering will be extended to allow for a period of five business days for the investor to reconfirm.

If the investor cancels his or her investment commitment during the period when cancellation is permissible, or does not reconfirm a commitment in the case of a material change to the investment, or the offering does not close, all of the investor's funds will be returned within five business days.

Within five business days of cancellation of an offering by the Company, the Company will give each investor notification of the cancellation, disclose the reason for the cancellation, identify the refund amount the investor will receive, and refund the investor's funds.

The Company's right to cancel. The Investment Agreement you will execute with us provides the Company the right to cancel for any reason before the offering deadline.

If the sum of the investment commitments from all investors does not equal or exceed the target offering amount at the time of the offering deadline, no securities will be sold in the offering. Investment commitments will be cancelled and committed funds will be returned.

In addition, we may cap at 450 the total number of investors who will be allowed to invest through the offering that are not "accredited investors," as defined in Rule 501(a) of Regulation D under the Securities Act of 1933. In the event that more than 450 non-accredited investors are initially accepted into an offering in step (2) described in Question 11, the Company may cancel investments based on the order in which payments by investors were received, or other criteria at the discretion of the Company, before the offering deadline.

Ownership and Capital Structure

THE OFFERING

13. Describe the terms of the securities being offered.

Priced Round: \$14,400,000.00 pre-money valuation

See exact security attached as Appendix B, Investor Contracts

Osnovium is offering up to 37,000 shares of Series Eseed Preferred Stock, at a price per share of \$30.00.

Investors in the first \$200,000.00 of the offering will receive stocks at a price per share of \$25.00, and a pre-money valuation of \$12,000,000.00

The campaign maximum is \$1,070,000.00 and the campaign minimum is \$60,750.00.

Irrevocable Proxy. The investor and his, her, or its transferees or assignees (collectively, the "Investor"), through a power of attorney granted by Investor in the Investor Agreement, will appoint XX Team LLC ("XX Team") as the Investor's true and lawful proxy and attorney (the "Proxy"), with the power to act alone and with full power of substitution, on behalf of the Investor to: (i) direct the voting of all securities held by the Investor, including the right to exercise the voting and other rights of Investor with respect to the Company's securities; and (ii) direct, in connection with such voting power, the execution of any instrument or document that XX Team determines is necessary and appropriate in the exercise of its authority. Such Proxy will be irrevocable. If an investor has entered into the Custodial and Voting Agreement with XX Investments LLC ("XX Investments"), then XX Investments will be the entity that XX Team directs to vote and take any other actions in connection with such voting (including the execution of documents) on behalf of such investor.

Repurchase. If the Company determines, in its sole discretion, that it is likely that within six months the securities of the Company will be held of record by a number of persons who are not "accredited investors" (as defined in Rule 405 of the Securities Exchange Act of 1934, as amended ("Exchange Act")), as required by Section 12(2) or 15(d) thereof, the Company shall have the option to repurchase the securities from each Investor for the greater of (i) the purchase price of the securities, and (ii) the fair market value of the securities, as determined by an independent appraiser of securities chosen by the Company. The foregoing repurchase option will terminate upon a Change of Control or Dissolution Event (each as defined in the Company's Subscription Agreement).

14. Do the securities offered have voting rights?

Yes

No

15. Are there any limitations on any voting or other rights identified above?

Yes

No. Irrevocable voting proxy granted to XX Team.

16. How may the terms of the securities being offered be modified?

Except as set forth in Section 3.(b) of the Subscription Agreement, and as otherwise specified in the Subscription Agreement, any term of this Agreement may be amended, terminated or waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the holders of a majority of the outstanding shares of Series Seed Preferred Stock (or Common Stock issued on conversion thereof). Notwithstanding the foregoing, the addition of a party to this Agreement pursuant to a transfer of Preferred Shares in accordance with applicable provisions of this Agreement will not require any further consent. Any amendment or waiver made in accordance with this paragraph will be binding upon the Purchaser, the Seller, each holder of the shares of Series Seed Preferred Stock (or the Common Stock issuable upon conversion thereof) or Common Stock, as applicable, and each future holder of all such securities, and the Company. It is specifically intended that entering into the Next Financing Agreements shall be considered an amendment to this Agreement provided that it is done in accordance with this Section.

RESTRICTIONS ON TRANSFER OF THE SECURITIES BEING OFFERED:

The securities being offered may not be transferred by any purchaser of such securities during the one year period beginning when the securities were issued, unless such securities are transferred:

1. to the issuing:
2. to an accredited investor;
3. as part of an offering registered with the U.S. Securities and Exchange Commission; or
4. to a member of the family of the purchaser or the equivalent, if not controlled by the purchaser, in a trust created for the benefit of a member of the family of the purchaser or the equivalent, or in connection with the death or divorce of the purchaser or other similar circumstances.

NOTE: The term "accredited investor" means any person who comes within any of the categories set forth in Rule 501(a) of Regulation D, or who the Seller reasonably believes comes within any of such categories, at the time of the sale of the securities to that person.

The term "member of the family of the purchaser or the equivalent" includes a child, stepchild, grandchild, parent, stepparent, grandparent, spouse or spousal equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law of the purchaser, and includes adoptive relationships. The term "spousal equivalent" means a cohabitant occupying a relationship generally equivalent to that of a spouse.

DESCRIPTION OF ISSUER'S SECURITIES

17. What other securities or classes of securities of the issuer are outstanding? Describe the material terms of any other outstanding securities or classes of securities of the issuer.

Class of Security	Securities (or Amount) Authorized	Securities (or Amount) Outstanding	Voting Rights
Common	500,000	480,000	Yes

Securities Reserved for Issuance upon Exercise or Conversion

Warrants:

Options:

Describe any other rights.

The company plans to authorize 37,000 shares of Preferred Stock in the near future, prior to the initial closing of the Wafunder raise. Preferred Stock will have preferred liquidation preferences and include voting rights.

18. How may the rights of the securities being offered be materially limited, diluted or quantified by the rights of any other class of security identified above?

The holders of a majority-in-interest of voting rights in the Company could limit the Investor's rights in a material way. For example, those interest holders could vote to change the terms of the agreements governing the Company's operations or cause the Company to engage in additional offerings (including potentially a public offering).

These changes could result in further limitations on the voting rights the Investor will have as an owner of equity in the Company, for example by diluting those rights or limiting them to certain types of events or consents.

To the extent applicable, in cases where the rights of holders of convertible debt, SAFES, or other outstanding options or warrants are exercised, or if new awards are granted under our equity compensation plans, an Investor's interests in the Company may be materially limited. This means that the portion of the Company represented by the Investor's securities will decrease, which could also dilute the Investor's voting and/or economic rights. In addition, as discussed above, if a majority-in-interest of holders of securities with voting rights cause the Company to issue additional equity, an investor's interest will typically also be diluted.

Based on the risk that an Investor's rights could be limited, diluted or otherwise quantified, the Investor could lose all or part of his or her investment in the securities in this offering, and may never see positive returns.

Additional risks related to the rights of other security holders are discussed below, in Question 20.

19. Are there any differences not reflected above between the securities being offered and each other class of security of the issuer?

No

20. How could the exercise of rights held by the principal shareholders identified in Question 6 above affect the purchasers of the securities being offered?

As holders of a majority-in-interest of voting rights in the Company, the shareholders may make decisions with which the Investor disagrees, or that negatively affect the value of the Investor's securities in the Company, and the Investor will have no recourse to change these decisions. The Investor's interests may conflict with those of other investors, and there is no guarantee that the Company will develop in a way that is optimal for or advantageous to the Investor.

For example, the shareholders may change the terms of the Articles of Incorporation for the company or the terms of the stock issued by the Company, including the management of the Company, and even dilute out minority holders of securities. The shareholders may make changes that affect the tax treatment of the Company in ways that are unfavorable to you but favorable to them. They may also vote to engage in new offerings and/or to register certain of the Company's securities in a way that negatively affects the value of the securities the Investor owns. Other holders of securities of the Company may also have access to the Investor's securities, which could give the Investor at a disadvantage with respect to any decisions regarding the exercise, no or the ownership. The shareholders have the right to redeem their securities at any time. Shareholders could decide to force the Company to redeem their securities at a time that is not favorable to the Investor and is damaging to the Company. Investors' exit may affect the value of the Company and/or its viability. In cases where the rights of holders of convertible debt, SAFES, or other outstanding options or warrants are exercised, or if new awards are granted under our equity compensation plans, an Investor's interests in the Company may be diluted. This means that the pro-rata portion of the Company represented by the Investor's securities will decrease, which could also dilute the Investor's voting and/or economic rights. In addition, as discussed above, if a majority-in-interest of holders of securities with voting rights cause the Company to issue additional stock, an Investor's interest will typically also be diluted.

Based on the risks described above, the Investor could lose all or part of his or her investment in the securities in this offering, and may never see positive returns.

21. How are the securities being offered being valued? Include examples of methods for how such securities may be valued by the issuer in the future, including during subsequent corporate actions.

The offering price for the securities offered pursuant to this Form C has been determined arbitrarily by the Company, and does not necessarily bear any relationship to the Company's book value, assets, earnings or other generally accepted valuation criteria. In determining the offering price, the Company did not employ investment banking firms or other outside organizations to make an independent appraisal or evaluation. Accordingly, the offering price should not be considered to be indicative of the actual value of the securities offered hereby.

In the future, we will perform valuations of our common stock that take into account factors such as the following:

1. unrelated third party valuations of our common stock;
2. the price at which we have issued securities, such as convertible debt or preferred Stock, in all of the rights, preferences and privileges of our those securities relative to those of our common stock;
3. our results of operations, financial position and capital resources;
4. current business conditions and projections;
5. the lack of marketability of our common stock;

6. the hiring of key personnel and the experience of our management;
7. the introduction of new products;
8. the risk inherent in the development and expansion of our products;
9. our stage of development and market position relative to our competitors;
10. the likelihood of achieving a liquidity event, such as an initial public offering or a sale of our company, given prevailing market conditions and the nature and history of our business;
11. industry trends and competitive environment;
12. trends in the economy, including consumer confidence;
13. overall economic indicators, including gross domestic product, employment, inflation and interest rates; and
14. the general economic outlook.

We will analyze factors such as those described above using a combination of financial and market-based methodologies to determine our business enterprise value. For example, we may use methodologies that assume that businesses operating in the same industry will share similar characteristics and that the Company's value will correlate to those characteristics, and/or methodologies that compare transactions in similar securities issued by us that were conducted in the market.

22. What are the risks to purchasers of the securities relating to minority ownership in the issuer?

An investor in the Company will likely hold a minority position in the Company, and thus be limited as to its ability to control or influence the governance and operations of the Company.

The inelasticity and value of the investor's interest in the Company will depend upon many factors outside the control of the investor. The Company will be managed by its officers and be governed in accordance with the strategic direction and decision-making of its Board Of Directors, and the investor will have no independent right to name or remove an officer or member of the Board Of Directors of the Company.

Following the investor's investment in the Company, the Company may sell interests to additional investors, which will dilute the percentage interest of the investor in the Company. The investor may have the opportunity to increase its investment in the Company in such a transaction, but such opportunity cannot be assured.

The amount of additional financing needed by the Company, if any, will depend upon the maturity and objectives of the Company. The declining of an opportunity or the inability of the investor to make a follow-on investment, or the lack of an opportunity to make such a follow-on investment, may result in substantial dilution of the investor's interest in the Company.

23. What are the risks to purchasers associated with corporate actions, including additional issuances of securities, issuer repurchases of securities, a sale of the issuer or assets of the issuer or the transfer of control of the issuer?

Additional issuances of securities. Following the investor's investment in the Company, the Company may sell interests to additional investors, which will dilute the percentage interest of the investor in the Company. The investor may have the opportunity to increase its investment in the Company in such a transaction, but such opportunity cannot be assured. The amount of additional financing needed by the Company, if any, will depend upon the maturity and objectives of the Company. The declining of an opportunity or the inability of the investor to make a follow-on investment, or the lack of an opportunity to make such a follow-on investment, may result in substantial dilution of the investor's interest in the Company.

Issuer repurchases of securities. The Company may have authority to repurchase its securities from shareholders, which may serve to decrease any liquidity in the market for such securities, decrease the percentage interests held by other similarly situated investors to the investor, and create pressure on the investor to sell its securities to the Company concurrently.

A sale of the issuer or assets of the issuer. As a minority owner of the Company, the investor will have limited or no ability to influence a potential sale of the Company or a substantial portion of its assets. Thus, the investor will rely upon the executive management of the Company and the Board of Directors of the Company to manage the Company so as to maximize value for shareholders. Accordingly, the success of the investor's investment in the Company will depend in large part upon the skill and expertise of the executive management of the Company, and the success of the Company's Board Of Directors of the Company in authorizing a sale of all or a portion of the Company, or a disposition of a substantial portion of the Company's assets, there can be no assurance that the value received by the investor, together with the fair market estimate of the value remaining in the Company, will be equal to or exceed the value of the investor's initial investment in the Company.

Transactions with related parties. The investor should be aware that there will be occasions when the Company may encounter potential conflicts of interest in its operations. On any issue involving conflicts of interest, the executive management and Board of Directors of the Company will be guided by their good faith judgement as to the Company's best interests. The Company may engage in transactions with related parties, including other companies, which may be on terms which are not arm's length, but will, in all cases, consistent with the duties of the management of the Company to its shareholders. By acquiring an interest in the Company, the investor will be deemed to have acknowledged the existence of any such actual or potential conflicts of interest and to have waived any claim with respect to any liability arising from the existence of any such conflict of interest.

24. Describe the material terms of any indebtedness of the issuer:

None

RESTRICTION TO QUESTION 24: name the creditor, amount owed, interest rate, maturity date, and any other material terms.

25. What other exempt offerings has the issuer conducted within the past three years?

Offering Date	Exemption	Security Type	Amount Sold	Use of Proceeds
				No exempt offerings.

26. Was or is the issuer or any entities controlled by or under common control with the issuer a party to any transaction since the beginning of the issuer's last fiscal year, or any currently proposed transaction, where the amount involved exceeds two percent of the aggregate amount of the issuer's assets or the amount involved in any proposed transaction, if any, during the preceding 12-month period, including the amount the issuer seeks to raise in the current offering, in which any of the following persons had or is to have a direct or indirect material interest:

1. any director or officer of the issuer;
2. any person who is, as of the most recent practicable date, the beneficial owner of 20 percent or more of the issuer's outstanding voting equity securities, calculated on the basis of voting power;
3. if the issuer was incorporated or organized within the past three years, any promoter of the issuer;
4. or (d) any immediate family member of any of the foregoing persons.

Yes

No

Beneficial ownership for purposes of paragraph (d) shall be determined as of a date when the issuer makes available to the date of filing of this offering statement and using the same calculations described in Question 6 of this Question and Answer Form.

The term "immediate family" includes any child, stepchild, grandchild, parent, stepparent, grandparent, spouse or spousal equivalent, sibling, mother in law, father in law, son in law, daughter in law, brother-in-law, or sister-in-law of the person, and includes adoptive relationships. The term "spousal equivalent" means a cohabitating couple or a relationship generally equivalent to that of a spouse.

Provide the amount of a related party's interest in any transaction without regard to the amount of the profit or loss involved in the transaction. If there is not practicable to state the approximate amount of the interest, describe the approximate amount involved in the transaction.

FINANCIAL CONDITION OF THE ISSUER

27. Does the issuer have an operating history?

Yes

No

28. Describe the financial condition of the issuer, including, to the extent material, liquidity, capital resources and historical results of operations.

Management's Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other financial information included elsewhere in this offering. Some of the information contained in this discussion and analysis is forward-looking information regarding the strategy and plans for our business, including forward-looking statements that involve risks and uncertainties. You should review the "Risk Factors" section for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

OsNovum has developed the technology to regenerate bone to maintain skeletal

health. Weak bones are a major reason for frailty as we age. OsNovum has the proven technology to regenerate bone but will also open clinics devoted exclusively to skeletal health and the prevention of frailty as we age.

In one year, we hope to introduce our technology to medicine for bone regeneration and open the initial clinics devoted to skeletal health. After two years, we hope to have additional revenue streams from pain management to expand OsNovum clinics worldwide. In 5 years, we hope that OsNovum will be recognized as the world leader in maintaining skeletal health with treatment facilities worldwide. These are forward looking projections and are not guaranteed.

Given the Company's limited operating history, the Company cannot reliably estimate how much revenue it will receive in the future, if any.

Milestones

OsNovum was incorporated in the State of Wyoming in June 2020.

Since then, we have:

- OsNovum has developed technology to grow bone and transform weak bone into healthy dense bone
- Gregory Gene Steiner, OsNovum's CEO, owns the patent to this technology
- OsNovum uses the patient's bone producing cells to grow their own bone back
- Patients seeking treatment for poor bone health will utilize OsNovum clinics
- OsNovum will utilize the world's leading scientists to help guide OsNovum clinicians
- Profits will be generated by our regenerative technology, but accelerated through OsNovum clinics

Historical Results of Operations

Our company was organized in June 2020 and has limited operations upon which prospective investors may base an evaluation of its performance.

- **Revenue & Gross Margin:** For the period ended August 11, 2020, the Company had revenues of \$0.
- **Assets:** As of August 11, 2020, the Company had total assets of \$0, including \$100 in cash.

- **Net Income:** The Company has had net income of \$0 for 2020.

- **Liabilities:** The Company's liabilities totaled \$0 for 2020.

Liquidity & Capital Resources

After the conclusion of this Offering, should we hit our minimum funding target, our projected runway is 3 months before we need to raise further capital.

We plan to use the proceeds as set forth in this Form C under "Use of Funds". We don't plan to use any other sources of capital in the immediate future.

We will likely require additional financing in excess of the proceeds from this Offering in order to perform operations over the lifetime of the Company. We plan to raise capital in 3 months. Except as otherwise described in this Form C, we do not have additional sources of capital other than the proceeds from the offering. Because of the complexities and uncertainties in establishing a new business strategy, it is not possible to adequately project whether the proceeds of this offering will be sufficient to enable us to implement our strategy. This complexity and uncertainty will be increased if less than the maximum amount of securities offered in this offering is sold. The Company intends to raise additional capital in the future from investors. Although capital may be available for early-stage companies, there is no guarantee that the Company will receive any investments from investors.

Runway & Short/Mid Term Expenses

OsNovum cash in hand is \$100, as of September 2020. Over the last three months, revenues have averaged \$0/month, cost of goods sold has averaged \$0/month, and operational expenses have averaged \$0/month, for an average burn rate of \$0 per month. Our intent is to be profitable in 12 months.

Since September 2020, there have been no major material changes or trends in our operations.

Years of research and development has been completed by SteinerBio. SteinerBio is leading OsNovum to market to Osteoporosis patients. Now, we are identifying clinical sites in order to test this technology to market. Once we could have FDA clearance within 6-12 months, before FDA clearance OsNovum will be aware of the pending clearance, and will begin marketing in preparation for distribution and profitability.

In the first 6 months, we hope to accomplish the following items with associated expenses: FDA tests, capital improvements, ISO certification, regulatory submission, legal, accounting, funding acquisition and salaries. This will cost approximately \$600K. After the first 6 months, we hope that our expenses will be: production equipment, product delivery system and salaries. This will cost approximately \$400K. Once we've achieved FDA clearance, we hope to start to see revenue, with COGS around 10%. Therefore, we hope that OsNovum will be immediately profitable. We hope that sales will gradually increase but will accelerate with the formation of OsNovum treatment facilities which will be slated for opening when FDA approval is achieved.

We will need around \$1M in total to launch OsNovum. If we do not raise enough on Wefunder, SteinerBio will provide funds to make up for any remaining deficits, in the form of an equity investment. We are raising on Wefunder, rather than fully relying on SteinerBio, as it will accelerate testing in order to bring OsNovum to market rapidly.

INSTRUCTIONS TO QUESTION 20: The discussion must cover each year for which financial statements are provided, for issuers with no prior operating history, the discussion should focus on financial milestones and operational, liquidity and other challenges. Issuers with an operating history should focus on the financial results for the most recent year and the nature of what has changed since the last financial year. Investors take into account the process of development and any other known or resulting source of capital. Investors have the records from developing and selling liquidity when reviewing these funds and any other additional funds necessary to the viability of the business, and how and/or the issuer anticipates using its available cash. Describe the other available sources of capital to the business, such as lines of credit or related contributions by shareholders. References to the issuer in this Question 20 and these instructions refer to the issuer and its predecessors, if any.

FINANCIAL INFORMATION

20. Include financial statements covering the two most recently completed fiscal years or the periods since inception, if shorter.

Refer to Appendix C, Financial Statements

I, Gregory Gene Steiner, certify that:

- (1) the financial statements of OsNovum included in this Form are true and complete in all material respects; and
- (2) the tax return information of OsNovum included in this Form reflects accurately the information reported on the tax return for OsNovum filed for the most recently completed fiscal year.

Gregory Gene Steiner
Biotech officer

STAKEHOLDER ELIGIBILITY

30. With respect to the issuer, any predecessor of the issuer, any affiliated issuer, any director, officer, general partner or managing member of the issuer, any beneficial owner of 20 percent or more of the issuer's outstanding voting equity securities, any promoter connected with the issuer in any capacity at the time of such sale, any person that has been or will be paid directly or indirectly compensation for the solicitation of purchases in connection with such sale of securities, or any general partner, director, officer or managing member of any such solicitor, prior to May 16, 2016:

(1) Has any such person been convicted, within 10 years (or five years, in the case of issuers, their predecessors and affiliated issuers), before the filing of this offering statement, of any felony or misdemeanor?

i. In connection with the purchase or sale of any security? Yes No

ii. Involving the making of any false filing with the Commission? Yes No

iii. Omitting out of the conduct of the business of an underwriter, broker, dealer, municipal securities dealer, investment adviser, funding portal or paid solicitor of purchasers of securities? Yes No

(2) Is any such person subject to any order, judgment or decree of any court of competent jurisdiction, entered within five years before the filing of the information required by Section 4(a)(2) of the Securities Act that, at the time of filing of this offering statement, restricts or prohibits such person from engaging or continuing to engage in any conduct or practice:

i. In connection with the purchase or sale of any security? Yes No

ii. Involving the making of any false filing with the Commission? Yes No

iii. Omitting out of the conduct of the business of an underwriter, broker, dealer, municipal securities dealer, investment adviser, funding portal or paid solicitor of purchasers of securities? Yes No

(3) Is any such person subject to a final order of a state securities commission (or an agency or office of a state performing like functions), a state authority that supervises or examines banks, savings associations or credit unions, a state insurance commission or an agency or

officer of a bank performing like functions); an appropriate federal banking agency; the U.S. Commodity Futures Trading Commission; or the National Credit Union Administration; that:

i. at the time of the filing of this offering statement bars the person from:
A. association with an entity regulated by such commission, authority, agency or officer? Yes No
B. engaging in the business of securities, insurance or banking? Yes No
C. engaging in savings association or credit union activities? Yes No

ii. constitutes a final order based on a violation of any law or regulation that prohibits, fraudulent, manipulation or deceptive conduct and for which the order was entered within the 10-year period ending on the date of the filing of this offering statement? Yes No

(4) Is any such person subject to an order of the Commission entered pursuant to Section 15(b) or 15(c) of the Exchange Act or Section 203(e), or (f) of the Investment Advisers Act of 1940 that prohibits, fraudulent, manipulation or deceptive conduct and for which the order was entered within the 10-year period ending on the date of the filing of this offering statement?

i. disqualifies or prohibits such person's registration as a broker, dealer, municipal securities dealer, investment adviser or funding portal? Yes No
ii. places limitations on the activities, functions or operations of such person? Yes No
iii. bars such person from being associated with any entity or from participating in the offering of any penny stock? Yes No

(5) Is any such person subject to any order of the Commission entered within five years before the filing of this offering statement, that at the time of the filing of this offering statement, orders the person to cease and desist from committing or causing a violation or future violation of:
i. any act, rule or regulation of the federal securities laws, including without limitation Section 701(n) of the Securities Act, Section 10(b) of the Exchange Act, Section 15(c)(1) of the Exchange Act and Section 206(e) of the Investment Advisers Act of 1940 or any other rule or regulation thereunder? Yes No
ii. Section 5 of the Securities Act? Yes No

(6) Is any such person suspended or disbarred from membership in, or suspended or barred from association with, a registered national securities exchange or a registered national or affiliated securities association for any act or omission to act constituting conduct inconsistent with just and equitable principles of trade? Yes No

(7) Has any such person filed as a respondent or relator, or was any such person or was any such person, a witness in, or otherwise involved in, the registration of Regulation A offering documents filed with the Commission within five years before the filing of this offering statement, was the subject of a refusal order, stop order, or order suspending the Regulation A exemption, or is any such person, at the time of such filing, the subject of an investigation or proceeding to determine whether a stop order or suspension order should be issued? Yes No

(8) Is any such person subject to a United States Postal Service letter representation order entered within five years before the filing of the information required by Section 14(d) of the Securities Act, or, is any such person, at the time of filing of this offering statement, subject to a temporary restraining order or preliminary injunction with respect to conduct alleged by the United States Postal Service to constitute a scheme or device for obtaining money or property through the mail by means of false representations? Yes No

If you would have answered "Yes" to any of these questions had the conviction, order, judgment, decree, suspension, expulsion or bar occurred or been issued after May 16, 2016, then you are NOT eligible to rely on this exemption under Section 4(a)(6) of the Securities Act.

INSTRUCTIONS TO QUESTION 10: Final order means a written directive or declaratory statement issued by a federal or state agency, described in Rule 101(a)(5) of Regulation Crowdfunding, under applicable statutory authority that provides for notice and an opportunity for hearing, which constitutes a final disposition or action by that federal or state agency.

This question is required to be disclosed with respect to issues relating to any affiliated issuer that occurred before the offering date, if the affiliated entity is not (a) a trustee of the issuer (b) under common control with the issuer by a third party that was in control of the affiliated entity at the time of such assets.

OTHER MATERIAL INFORMATION

3. In addition to the information expressly required to be included in this Form, include:

- (1) any other material information presented to investors; and
- (2) such further material information, if any, as may be necessary to make the required statements, in the light of the circumstances under which they are made, not misleading.

The Company is using the services of XX as part of its offering. XX is comprised of XX Investments, LLC, XX Team LLC, and the Lead Investors who provide services on behalf of XX Team LLC. The services of XX are available to companies that offer securities through Wefunder Portal LLC and to investors who invest in such companies through Wefunder Portal, but XX is not affiliated with Wefunder Portal or its affiliates.

XX Investments is the Company's transfer agent and also acts as custodian, paying agent, and proxy agent on behalf of all investors that enter into the Custodian and Voting Agreements with XX Investments through the Wefunder Portal website ("Investor"). XX Investments holds legal title to the securities the Company issues through Wefunder Portal (which are uncircumfected) on behalf of Investors. Investors, in turn, hold the beneficial interests in the Company's securities. XX Investments keeps track of each investor's beneficial ownership interest and makes any distributions to the investors (or other parties, as directed by the investors).

In addition to the above services, at the direction of XX Team, XX Investments votes the securities and take any other actions in connection with such voting on behalf of the investors. XX Investments acts at the direction of XX Team, because XX Team holds a power of attorney from each investor that has entered into the Investor Agreement to vote securities on behalf of the investor. XX Investments will not charge investors for its services. XX Investments does charge the Company \$1,000/year for services; however, those fees may be paid by Wefunder Inc. on behalf of the Company.

As noted, XX Team holds a power of attorney from each investor that has entered into the Investor Agreement to make voting decisions on behalf of that investor. Pursuant to the power of attorney, XX Team will make voting decisions and then direct XX Investments to vote and take any other actions in connection with the voting on investors' behalf. XX Team will act, with respect to the Company, through our Lead Investor, who is a representative of XX Team. As compensation for its voting services, the Lead Investor is entitled to receive a fee of 10% of XX Team's 10% of any distributions that the investor would otherwise receive from the Company. XX Team will also provide consulting services to the Company and may be compensated for those services by the Company; although, fees owed by the Company may be paid by Wefunder Inc. XX Team will share its consulting compensation with our Lead Investor.

The Lead Investor is an experienced investor that we choose to act in the role of Lead Investor, both on behalf of the Company and on behalf of Investors. As noted, the Lead Investor will be a representative of XX Team and will share in compensation for its services from the Company and Wefunder Inc. on the Company's behalf or from Investors. The Lead Investor will be appointed by the Company and approved by Wefunder Inc. and the identity of the Lead Investor must be disclosed to Investors before Investors make a final investment decision to purchase the Company's securities. Investors will receive disclosure regarding all fees that may be received by the Lead Investor. In addition to the fees described above, the Lead Investor may receive compensation if, in the future, Wefunder Inc. or the Company enters into a relationship with another party for the purpose of investing in a non-Regulation Crowdfunding offering of the Company. In such a circumstance, the Lead Investor may act as a portfolio manager for that SPV (and as a supervised person of Wefunder Advisor) and may be compensated through that role. Although the Lead Investor may act in multiple roles and be compensated from multiple parties, the Lead Investor's goal is to maximize the value of the Company and therefore maximize the value of the Company's securities. As a result, the Lead Investor's interests should always be aligned with those of the investors.

Investors that wish to purchase the Company's securities through Wefunder Portal must agree to (1) hire XX Investments to serve as custodian, paying agent, and proxy agent with respect to the Company's securities; (2) name a power of attorney to XX Team to make all voting decisions with respect to the Company's securities; and (3) direct XX Investments to share 10% of the investors' distribution from the Company with XX Team. The Company may waive these requirements for certain investors with whom the Company has a pre-existing relationship.

The XX arrangement described above is intended to benefit the Company by allowing the Company to reflect one investor of its capitalization table (XX Investments) and by simplifying the voting process with respect to the Company's securities by having one entity (XX Team), through one person (the Lead Investor), make all voting decisions and having one entity (XX Investments) carry out XX Team's direction. The XX arrangement is intended to benefit the Company. This arrangement also is intended to benefit Investors by providing the services of an experienced Lead Investor (acting on behalf of XX Team) who is expected to make value-maximizing decisions regarding investors' securities. XX Team (acting through the Lead Investor) may further benefit both the Company and Investors by providing consulting services to the Company that are intended to maximize both the value of the Company's business and also the value of its securities.

INSTRUCTIONS TO QUESTION 11: Information is intended to investors in a format made or other means not able to be received in a text or portable document format, the issuer should include:
(a) a description of the material content of such information;
(b) a description of the format in which such disclosure is presented; and
(c) the ease of disclosure in video, audio or other dynamic media or format, a transcript or description of such disclosure.

ONGOING REPORTING

32. The issuer will file a report electronically with the Securities & Exchange Commission annually and post the report on its website, no later than:

120 days after the end of each fiscal year covered by the report.

33. Once posted, the annual report may be found on the issuer's website at: <http://www.OsNovum.com/invest>

The issuer must continue to comply with the ongoing reporting requirements until:

1. the issuer is required to file reports under Exchange Act Sections 13(a) or 15(g);
2. the issuer has filed at least one annual report and has fewer than 300 holders of record;
3. the issuer has filed at least three annual reports and has total assets that do not exceed \$10 million;
4. the issuer or another party purchases or repurchases all of the securities issued pursuant to Section 4(a)(6), including any payment in full of debt securities or any complete redemption of redeemable securities; or the issuer liquidates or dissolves in accordance with state law.

APPENDICES

[Appendix A: Business Description & Plan](#)

[Appendix B: Investor Contracts](#)

[Early Bird OsNovum Subscription Agreement Final](#)
[OsNovum Subscription Agreement Final](#)

[Appendix C: Financial Statements](#)

[Financials 1](#)

[Appendix D: Director & Officer Work History](#)

[Daniel Vargas](#)
[Gregory Gene Steiner](#)
[Roslyn Lilian Steiner](#)

[Appendix E: Supporting Documents](#)

[OsNovum_Early_Bird_Term_Sheet.pdf](#)
[OsNovum-Regular_Bird_Term_Sheet.pdf](#)

Signatures

Intentional misstatements or omissions of facts constitute federal criminal violations. See 18 U.S.C. 1001.

The following documents will be filed with the SEC:

[Cover Page XML](#)

[Offering Statement \(this page\)](#)

[Appendix A: Business Description & Plan](#)

[Appendix B: Investor Contracts](#)

[Early Bird OsNovum Subscription Agreement Final](#)
[OsNovum Subscription Agreement Final](#)

[Appendix C: Financial Statements](#)

[Financials 1](#)

[Appendix D: Director & Officer Work History](#)

[Daniel Vargas](#)
[Gregory Gene Steiner](#)
[Roslyn Lilian Steiner](#)

[Appendix E: Supporting Documents](#)

[OsNovum_Early_Bird_Term_Sheet.pdf](#)
[OsNovum-Regular_Bird_Term_Sheet.pdf](#)

Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100 et seq.), the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form C and has duly caused this Form to be signed on its behalf by the duly authorized undersigned.

OsNovum

By

Gregory Steiner
CEO SteinerBio and OsNovum

Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100 et seq.), this Form C and Transfer Agent Agreement has been signed by the following persons in the capacities and on the dates indicated.

Roslyn Lilian Steiner

President

2/24/2021

Gregory Steiner
CEO SteinerBio and OsNovum
2/17/2021

The Form C must be signed by the issuer, its principal executive officer or officers, its principal financial officer, its controller or principal accounting officer and at least a majority of the board of directors or persons performing similar functions.

I authorize Wefunder Portal to submit a Form C to the SEC based on the information I provided through this online form and my company's Wefunder profile.

As an authorized representative of the company, I appoint Wefunder Portal as the company's true and lawful representative and attorney-in-fact, in the company's name, place and stead to make, execute, sign, acknowledge, swear to and file a Form C on the company's behalf. This power of attorney is coupled with an interest and is irrevocable. The company hereby waives any and all defenses that may be available to contest, negate or disaffirm the actions of Wefunder Portal taken in good faith under or in reliance upon this power of attorney.